Inositec founder Mattias Ivarsson finished 3rd at the 2015 Venture-Finals
Developing small molecules as alternatives to antibiotics
Inositec will pursue the preclinical and early clinical development of a novel non-antibiotic treatment against Clostridium difficile infection. Clostridium difficile is the leading cause of potentially deadly gastro-intestinal infections caused by antibiotic treatment in healthcare settings.
Silke Meyns from ETH Transfer summarized the jury’s opinion of Inositec’s business plan as follows:
“The approach of Inositec is very innovative since it uses a mechanism which prevents damage to the patient and avoids resistances like with antibiotics. The use of an easily accessible small molecule will make it possible to achieve the proof of concept stage fast. Tests with animals have already shown positive results.
The team combines strong scientific and business experience and has great potential to translate this technology into the clinic.”